Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles
Eye drops containing Tranilast (TL), N-(3,4-dimethoxycinnamoyl) anthramilic acid, are used as an anti-allergic conjunctivitis drug in the ophthalmic field. Traditional eye drops are very patient compliant, although the bioavailability (<i>BA</i>) of most eye drops is low since eye drops...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Materials |
Subjects: | |
Online Access: | https://www.mdpi.com/1996-1944/13/7/1675 |
id |
doaj-fff6b5a966824513ac7963af1bcd6513 |
---|---|
record_format |
Article |
spelling |
doaj-fff6b5a966824513ac7963af1bcd65132020-11-25T03:10:55ZengMDPI AGMaterials1996-19442020-04-01131675167510.3390/ma13071675Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid NanoparticlesMisa Minami0Ryotaro Seiriki1Hiroko Otake2Yosuke Nakazawa3Kazutaka Kanai4Tadatoshi Tanino5Noriaki Nagai6Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, JapanFaculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, JapanFaculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, JapanFaculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, JapanDepartment of Small Animal Internal Medicine, School of Veterinary Medicine, University of Kitasato, Towada, Aomori 034-8628, JapanFaculty of Pharmaceutical Sciences, Tokushima Bunri University, 180 Yamashiro-Cho, Tokushima 770-8514, JapanFaculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, JapanEye drops containing Tranilast (TL), N-(3,4-dimethoxycinnamoyl) anthramilic acid, are used as an anti-allergic conjunctivitis drug in the ophthalmic field. Traditional eye drops are very patient compliant, although the bioavailability (<i>BA</i>) of most eye drops is low since eye drops cannot be instilled beyond the capacity of the conjunctival sac due to its limited volume. Thus, traditional eye drops have low <i>BA</i> and a short duration of the drug on the ocular surface, so solutions to these problems are highly anticipated. In this study, we designed a sustained-release drug-delivery system (DDS) for TL nanoparticles. TL nanoparticles were prepared by bead mill treatment, and the gel formulations containing TL nanoparticles (TL-NPs-Gel, particle size 50 nm–100 nm) were provided by carboxypolymethylene. The crystal structure of TL with and without bead mill treatment is the same, but the TL solubility in formulations containing nanoparticles was 5.3-fold higher compared with gel formulations containing TL microparticles (TL-MPs-Gel). The photo and thermal stabilities of TL-NPs-Gel are also higher than those of dissolved TL. Moreover, when TL-NPs-Gel is applied to the upper eyelid skin (outside), the TL is released as nanoparticles, and delivered to the lacrimal fluid through the meibomian glands. In addition, the TL release profile for TL-NPs-Gel was sustained over 180 min after the treatment. These findings can be used to develop a sustained-release DDS in the ophthalmic field.https://www.mdpi.com/1996-1944/13/7/1675tranilastsustained delivery systemlacrimal fluideyelidmeibomian glands |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Misa Minami Ryotaro Seiriki Hiroko Otake Yosuke Nakazawa Kazutaka Kanai Tadatoshi Tanino Noriaki Nagai |
spellingShingle |
Misa Minami Ryotaro Seiriki Hiroko Otake Yosuke Nakazawa Kazutaka Kanai Tadatoshi Tanino Noriaki Nagai Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles Materials tranilast sustained delivery system lacrimal fluid eyelid meibomian glands |
author_facet |
Misa Minami Ryotaro Seiriki Hiroko Otake Yosuke Nakazawa Kazutaka Kanai Tadatoshi Tanino Noriaki Nagai |
author_sort |
Misa Minami |
title |
Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles |
title_short |
Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles |
title_full |
Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles |
title_fullStr |
Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles |
title_full_unstemmed |
Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles |
title_sort |
development of sustained-release ophthalmic formulation based on tranilast solid nanoparticles |
publisher |
MDPI AG |
series |
Materials |
issn |
1996-1944 |
publishDate |
2020-04-01 |
description |
Eye drops containing Tranilast (TL), N-(3,4-dimethoxycinnamoyl) anthramilic acid, are used as an anti-allergic conjunctivitis drug in the ophthalmic field. Traditional eye drops are very patient compliant, although the bioavailability (<i>BA</i>) of most eye drops is low since eye drops cannot be instilled beyond the capacity of the conjunctival sac due to its limited volume. Thus, traditional eye drops have low <i>BA</i> and a short duration of the drug on the ocular surface, so solutions to these problems are highly anticipated. In this study, we designed a sustained-release drug-delivery system (DDS) for TL nanoparticles. TL nanoparticles were prepared by bead mill treatment, and the gel formulations containing TL nanoparticles (TL-NPs-Gel, particle size 50 nm–100 nm) were provided by carboxypolymethylene. The crystal structure of TL with and without bead mill treatment is the same, but the TL solubility in formulations containing nanoparticles was 5.3-fold higher compared with gel formulations containing TL microparticles (TL-MPs-Gel). The photo and thermal stabilities of TL-NPs-Gel are also higher than those of dissolved TL. Moreover, when TL-NPs-Gel is applied to the upper eyelid skin (outside), the TL is released as nanoparticles, and delivered to the lacrimal fluid through the meibomian glands. In addition, the TL release profile for TL-NPs-Gel was sustained over 180 min after the treatment. These findings can be used to develop a sustained-release DDS in the ophthalmic field. |
topic |
tranilast sustained delivery system lacrimal fluid eyelid meibomian glands |
url |
https://www.mdpi.com/1996-1944/13/7/1675 |
work_keys_str_mv |
AT misaminami developmentofsustainedreleaseophthalmicformulationbasedontranilastsolidnanoparticles AT ryotaroseiriki developmentofsustainedreleaseophthalmicformulationbasedontranilastsolidnanoparticles AT hirokootake developmentofsustainedreleaseophthalmicformulationbasedontranilastsolidnanoparticles AT yosukenakazawa developmentofsustainedreleaseophthalmicformulationbasedontranilastsolidnanoparticles AT kazutakakanai developmentofsustainedreleaseophthalmicformulationbasedontranilastsolidnanoparticles AT tadatoshitanino developmentofsustainedreleaseophthalmicformulationbasedontranilastsolidnanoparticles AT noriakinagai developmentofsustainedreleaseophthalmicformulationbasedontranilastsolidnanoparticles |
_version_ |
1724656374439215104 |